Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ARWR – Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
ARWR
$16.03
Name : Arrowhead Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,213,052,416.00
EPSttm : -1.24
finviz dynamic chart for ARWR
Arrowhead Pharmaceuticals, Inc.
$16.03
0.34%
$0.055

Float Short %

11.01

Margin Of Safety %

-31

Put/Call OI Ratio

0.6

EPS Next Q Diff

-3.17

EPS Last/This Y

4.97

EPS This/Next Y

-3.27

Price

16.08

Target Price

41.77

Analyst Recom

1.62

Performance Q

16.52

Relative Volume

1.09

Beta

0.95

Ticker: ARWR




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02ARWR16.41.390.1836226
2025-06-03ARWR16.611.370.0836469
2025-06-04ARWR16.741.360.1336587
2025-06-05ARWR16.461.360.0536757
2025-06-06ARWR16.81.360.1436773
2025-06-09ARWR16.571.350.0036851
2025-06-10ARWR16.981.350.0436899
2025-06-11ARWR16.751.340.9436993
2025-06-12ARWR16.231.345.3337267
2025-06-13ARWR15.751.310.1536751
2025-06-16ARWR15.71.320.9636677
2025-06-17ARWR15.491.320.1436836
2025-06-18ARWR15.621.310.4436684
2025-06-20ARWR15.321.300.7636485
2025-06-23ARWR15.510.600.6514283
2025-06-24ARWR15.940.600.0014374
2025-06-25ARWR15.650.601.2614473
2025-06-26ARWR16.070.600.2314599
2025-06-27ARWR16.080.600.4814621
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02ARWR16.4220.2451.0-0.18
2025-06-03ARWR16.6120.2-303.1-0.18
2025-06-04ARWR16.7420.2-300.1-0.18
2025-06-05ARWR16.4620.2-286.6-0.18
2025-06-06ARWR16.7920.2-307.5-0.18
2025-06-09ARWR16.5720.2-288.0-0.18
2025-06-10ARWR16.9720.2-309.5-0.18
2025-06-11ARWR16.7420.2-288.5-0.18
2025-06-12ARWR16.2220.2-278.6-0.18
2025-06-13ARWR15.7420.2-279.2-0.18
2025-06-16ARWR15.6920.2-294.1-0.18
2025-06-17ARWR15.5020.2-288.7-0.18
2025-06-18ARWR15.6220.2-300.4-0.18
2025-06-20ARWR15.3220.2-285.0-0.18
2025-06-23ARWR15.5320.2-304.3-0.18
2025-06-24ARWR15.9420.2-311.8-0.18
2025-06-25ARWR15.6520.2-285.0-0.18
2025-06-26ARWR16.05- -310.60.00
2025-06-27ARWR16.08- -296.2-0.18
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02ARWR-2.905.2411.50
2025-06-03ARWR-2.905.2411.50
2025-06-04ARWR-2.905.2411.50
2025-06-05ARWR-2.905.2411.50
2025-06-06ARWR-2.905.2411.50
2025-06-09ARWR-2.905.2711.50
2025-06-10ARWR-2.905.2711.50
2025-06-11ARWR-2.905.2711.55
2025-06-12ARWR-2.905.2711.55
2025-06-13ARWR-2.905.2711.55
2025-06-16ARWR-2.905.2211.55
2025-06-18ARWR-2.905.2211.55
2025-06-20ARWR-2.815.2211.55
2025-06-23ARWR-2.705.2511.55
2025-06-24ARWR-2.655.2511.55
2025-06-25ARWR-2.655.2511.55
2025-06-26ARWR-2.655.2511.01
2025-06-27ARWR-2.655.2511.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

2.75

Avg. EPS Est. Current Quarter

-1.1

Avg. EPS Est. Next Quarter

-0.42

Insider Transactions

-2.65

Institutional Transactions

5.25

Beta

0.95

Average Sales Estimate Current Quarter

29

Average Sales Estimate Next Quarter

115

Fair Value

11.02

Quality Score

35

Growth Score

44

Sentiment Score

43

Actual DrawDown %

82.8

Max Drawdown 5-Year %

-89

Target Price

41.77

P/E

Forward P/E

PEG

P/S

4.07

P/B

3.25

P/Free Cash Flow

482.75

EPS

-1.38

Average EPS Est. Cur. Y​

-0.18

EPS Next Y. (Est.)

-3.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.41

Relative Volume

1.09

Return on Equity vs Sector %

-45

Return on Equity vs Industry %

-27.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-296.2
Arrowhead Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 609
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading